临床试验/NCT03952039

NCT03952039已完成3 期

A Phase 3, Multicenter, Open-label, Randomized Study to Evaluate the Efficacy and Safety of Fedratinib Compared to Best Available Therapy (BAT) in Subjects With DIPSS (Dynamic International Prognostic Scoring System)-Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) and Previously Treated With Ruxolitinib

Celgene107 个研究点分布在 8 个国家目标入组 202 人开始时间: 2019年9月9日最近更新: 2025年8月28日

适应症

干预措施

试验速览

阶段: 3 期
状态: 已完成
发起方: Celgene
入组人数: 202
试验地点: 107
主要终点: Spleen Volume Response Rate (RR)

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验相关资讯

研究概览

简要总结

A Phase 3, multicenter, open-label, randomized study to evaluate the efficacy and safety of fedratinib compared to best available therapy (BAT) in subjects with DIPSS (Dynamic International Prognostic Scoring System)-intermediate or high-risk primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (post-PV MF), or post-essential thrombocythemia myelofibrosis (post-ET MF) and previously treated with ruxolitinib. The primary objective of the study is to evaluate the percentage of subjects with at least 35% spleen volume reduction in the fedratinib and the BAT arms.

详细描述

This Phase 3, multicenter, randomized, two-arm, open-label study will include subjects with intermediate or high-risk (as per the DIPSS score) primary myelofibrosis (PMF), postpolycythemia vera myelofibrosis (post-PV MF), or post-essential thrombocythemia myelofibrosis (post-ET MF). This study will be conducted in compliance with International Council for Harmonisation (ICH) Good Clinical Practices (GCPs).

Study design includes:

A 28-day Screening Period
2:1 Randomization to fedratinib or best available therapy (BAT)
Stratification at Randomization according to:
Spleen size by palpation: < 15 cm below left costal margin (LCM) versus ≥ 15 cm below LCM
Platelets ≥ 50 to < 100 x 109/L versus platelets ≥ 100 x 109/L
Refractory or relapsed to ruxolitinib treatment versus intolerant to ruxolitinib treatment
Study Treatment Period (time on study drug plus 30 days after last dose)
Subjects are allowed to crossover from BAT to the fedratinib arm after the Cycle 6 response assessment or before the Cycle 6 response assessment in the event of a confirmed progression of splenomegaly by MRI/CT scan
A Survival Follow-up Period for progression and survival

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Parallel
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Subject is at least 18 years of age at the time of signing the informed consent form (ICF)
•Subject has an Eastern Cooperative Oncology Group (ECOG) Performance Score (PS) of 0, 1 or 2
•Subject has diagnosis of primary myelofibrosis (PMF) according to the 2016 World Health Organization (WHO) criteria, or diagnosis of post-ET or post-PV myelofibrosis according to the IWG-MRT 2007 criteria, confirmed by the most recent local pathology report
•Subject has a DIPSS Risk score of Intermediate-2 or High
•Subject has a measurable splenomegaly during the screening period as demonstrated by spleen volume of ≥ 450 cm3 by MRI or CT-scan and by palpable spleen measuring ≥ 5 cm below the left costal margin
•Subject has a measurable total symptoms score (≥ 1) as measured by the Myelofibrosis Symptom Assessment Form (MFSAF)
•Subject has been previously exposed to ruxolitinib, and must meet at least one of the following criteria (a and/or b)
•Treatment with ruxolitinib for ≥ 3 months with inadequate efficacy response (refractory) defined as < 10% spleen volume reduction by MRI or < 30% decrease from baseline in spleen size by palpation or regrowth (relapsed) to these parameters following an initial response
•Treatment with ruxolitinib for ≥ 28 days complicated by any of the following (intolerant):
•Development of a red blood cell transfusion requirement (at least 2 units/month for 2 months) or
•Grade ≥ 3 AEs of thrombocytopenia, anemia, hematoma, and/or hemorrhage while on treatment with ruxolitinib
•Subject must have treatment-related toxicities from prior therapy resolved to Grade 1 or pretreatment baseline before start of last therapy prior to randomization
•Subject must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted
•Subject is willing and able to adhere to the study visit schedule and other protocol requirements
•A female of childbearing potential (FCBP) must:
•Have 2 negative pregnancy tests as verified by the Investigator during screening prior to starting study treatment. She must agree to ongoing pregnancy testing during the course of the study, and after end of study treatment. This applies even if the subject practices true abstinence from heterosexual contact.
•Either commit to true abstinence from heterosexual contact (which must be reviewed on a monthly basis and source documented) or agree to use and be able to comply with highly effective contraception without interruption, -14 days prior to starting investigational product, during the study treatment (including dose interruptions), and for 30 days after discontinuation of study treatment.
•Note: A female of childbearing potential (FCBP) is a female who: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy, or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (ie, has had menses at any time in the preceding 24 consecutive months).
•A male subject must:
•Practice true abstinence (which must be reviewed on a monthly basis) or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for at least 30 days following investigational product discontinuation, or longer if required for each compound and/or by local regulations, even if he has undergone a successful vasectomy

排除标准

•Any of the following laboratory abnormalities:
•Platelets < 50 x 109/L
•Absolute neutrophil count (ANC) < 1.0 x 109/L
•White blood count (WBC) > 100 x 109/L
•Myeloblasts ≥ 5 % in peripheral blood
•Estimated glomerular filtration rate < 30 mL/min/1.73 m2 (as per the Modification of Diet in Renal Disease [MDRD] formula)
•Serum amylase or lipase > 1.5 x upper limit of normal (ULN)
•Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 x upper limit of normal (ULN)
•Total bilirubin > 1.5 x ULN, subject's total bilirubin between 1.5 - 3.0 x ULN are eligible if the direct bilirubin fraction is < 25% of the total bilirubin
•Subject is pregnant or lactating female
•Subject with previous splenectomy
•Subject with previous or planned hematopoietic cell transplant
•Subject with prior history of encephalopathy, including Wernicke's (WE)
•Subject with signs or symptoms of encephalopathy, including WE (eg, severe ataxia, ocular paralysis or cerebellar signs)
•Subject with thiamine deficiency, defined as thiamine levels in whole blood below normal range according to the central laboratory and not demonstrated to be corrected prior to randomization
•Subject with concomitant treatment with or use of pharmaceutical, herbal agents or food known to be strong or moderate inducers of Cytochrome P450 3A4 (CYP3A4), or dual CYP2C19 and CYP3A4 inhibitors
•Subject on any chemotherapy, immunomodulatory drug therapy (eg, thalidomide, interferon-alpha), anagrelide, immunosuppressive therapy, systemic corticosteroids > 10 mg/day prednisone or equivalent. Subjects who have had prior exposure to hydroxyurea (eg, Hydrea) in the past may be enrolled into the study as long as it has not been administered within 14 days prior to randomization
•Subject has received ruxolitinib within 14 days prior to randomization
•Subject with previous exposure to Janus kinase (JAK) inhibitor(s) other than ruxolitinib treatment
•Subject on treatment with aspirin with doses > 150 mg daily
•Subject with major surgery within 28 days prior to randomization
•Subject with diagnosis of chronic liver disease (eg, chronic alcoholic liver disease, autoimmune hepatitis, sclerosing cholangitis, primary biliary cirrhosis, hemochromatosis, non-alcoholic steatohepatitis)
•Subject with prior malignancy other than the disease under study unless the subject has not required treatment for the malignancy for at least 3 years prior to randomization. However, subject with the following history/concurrent conditions provided successfully treated may enroll: non-invasive skin cancer, in situ cervical cancer, carcinoma in situ of the breast, incidental histologic finding of prostate cancer (T1a or T1b using the tumor, nodes, metastasis [TNM] clinical staging system), or is free of disease and on hormonal treatment only
•Subject with uncontrolled congestive heart failure (New York Heart Association Classification 3 or 4)
•Subject with known human immunodeficiency virus (HIV), known active infectious Hepatitis B (HepB), and/or known active infectious Hepatitis C (HepC)
•Subject with serious active infection
•Subject with presence of any significant gastric or other disorder that would inhibit absorption of oral medication
•Subject is unable to swallow capsule
•Subject with any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study
•Subject has any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study
•Subject has any condition that confounds the ability to interpret data from the study
•Subject with participation in any study of an investigational agent (drug, biologic, device) within 30 days prior to randomization
•Subject with a life expectancy of less than 6 months

研究组 & 干预措施

Fedratinib 400mg/day

Experimental

Will include up to 128 subjects receiving fedratinib 400 mg self-administered Investigational Product (IP) on an outpatient basis, once daily preferably together with food during an evening meal at the same time each day in consecutive 4-week (28-day) cycles.

干预措施: FEDRATINIB (Drug)

Best Available Therapy (BAT)

Active Comparator

Best-available Investigator-selected therapy included a number of available compounds to treat MF and/or its symptoms and was chosen by the investigator for each subject. Therapy changed at different times during the treatment period. No investigational agents (e.g. not approved for the treatment of any indication) were allowed. BAT also included the choice of no treatment.

干预措施: Best Available Therapy (BAT) (Drug)

结局指标

主要结局

Spleen Volume Response Rate (RR)

时间窗: From Screening to end of Cycle 6 (1 cycle = 28 days), approximately 196 days

Percentage of participants who have ≥ 35% spleen volume reduction (SVR) at end of cycle 6 A Cochran-Mantel-Haenszel (CMH) test to adjust for planned stratification factors (spleen size by palpation, platelet counts and refractory/relapsed or intolerance to ruxolitinib treatment). The RRs and 95% confidence intervals (CI) will be provided for each arm as well as for the difference in RRs and 95% confidence interval of the difference for fedratinib to BAT.

次要结局

Spleen Response Rate by Palpation (RRP)(From Cycle 1 Dose 1 to end of Cycle 6, approximately 168 days)
Symptom Response Rate (SRR)(From Cycle 1 Dose 1 to end of Cycle 6, approximately 168 days)
Spleen Volume Response Rate (RR25)(From Screening to end of Cycle 6 (1 cycle = 28 days), approximately 196 days)
Number of Participants With All Grade Treatment Emergent Adverse Events (AEs) and Grade 3 to 4 Treatment Emergent AEs(From Cycle 1 Dose 1 to end of Cycle 6, approximately 168 days)
Number of Participants With Hematology Laboratory Abnormalities(From Cycle 1 Dose 1 to end of Cycle 6, approximately 168 days)
Durability of Spleen Volume Response (DR)(From baseline to end of treatment visit, Approximately on average 53 weeks up to 151 weeks.)
Durability of Spleen Response by Palpation (DRP)(From baseline to end of treatment visit, Approximately on average 53 weeks up to 151 weeks.)
Assessment of the Effectiveness of Risk Mitigation Strategy for ≥3 Grade Gastrointestinal Adverse Events and Any Grade Wernickes Encephalopathy(From Screening to end of Cycle 6 (1 cycle = 28 days), approximately 196 days)
Overall Survival(From Randomization to the end of Survival Follow Up)
Durability of Symptoms Response (DSR)(From baseline to end of treatment visit, Approximately on average 53 weeks up to 151 weeks.)
Number of Participants With Thiamine Levels Below the Lower Limit of Normal(From Cycle 1 Dose 1 to end of Cycle 6, approximately 168 days)
Mean Change in EORTC QOL-C30 at Cycle 7 Day 1 as Compared With Baseline(from the start of cycle 1 to cycle 7 day 1 approximately 170 days.)
Mean Change From Baseline in EQ-5D-5L Utility Index Score(from the start of cycle 1 to cycle 7 day 1 approximately 170 days.)
Time to Spleen and Disease Progression Free Survival (SDPFS)(From randomization to the End of Survival Follow-up)

研究者

发起方

Celgene

申办方类型

Industry

责任方

Sponsor

研究点 (107)

Loading locations...

相似试验

进行中（未招募）

3 期

Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic LeukemiaUntreated Chronic Lymphocytic Leukemia

NCT04075292AstraZeneca155

招募中

2 期

Multicenter, Phase II Randomized Controlled Study of Adebrelimab Combined With Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC)Small Cell Lung Cancer Extensive Stage

NCT06610734Sichuan University202

进行中（未招募）

3 期

Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After ProstatectomyProstate Cancer

NCT04181203UNICANCER490

终止

3 期

A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical ResectionCarcinoma, Transitional Cell

NCT02450331Hoffmann-La Roche809

撤回

3 期

Efficacy and Safety Study of Formoterol/Fluticasone and Salmeterol/Fluticasone in Patients With Moderate-to-severe COPDChronic Obstructive Pulmonary DiseaseCOPD

NCT01393145Ache Laboratorios Farmaceuticos S.A.